Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PR3124 FINALS > Pneumonia > Flashcards

Pneumonia Flashcards

1
Q

What is pneumonia?

A

A lower respiratory tract infection of the lung parenchyma, due to proliferation of microbial pathogens in the alveolar level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the mechanisms in which bacteria enters the lower respiratory tract?

A

Aspiration of oropharyngeal secretions, inhalation of aerosols, hematogenous spreading

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How is pneumonia diagnosed?

A

Signs and symptoms (cough, chest pains, SOB, hypoxia, fever, chills, tachypnea, tachycardia, hypotension, leukocytosis, fatigue, anorexia, nausea, changes in mental status)

Physical examination (diminished breath sounds over the affected area, inspiratory crackles during lung expansion)

Radiographic findings (chest XR or CT, looking for new infiltrates or dense consolidations)

Laboratory findings (e.g. CRP, procalcitonin)

Respiratory cultures (sputum, lower respiratory tract samples)

Blood cultures

Urinary antigen tests (Streptococcus pneumonia, Legionella pneumophilia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is community-acquired pneumonia?

A

onset in the community or < 48 hours after hospital admission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are risk factors for CAP?

A

Age >=65 years
Previous hospitalisation for CAP
Smoking
COPD, DM, HF, cancer, immunosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prevention methods for CAP?

A

Smoking cessation

Immunisations (influenza, pneumococcal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Outpatient microbiology for CAP

A

Haemophilus influenzae
Streptococcus pneumoniae
Atypicals (Mycoplasma pneumoniae, chlamydophilia pneumoniae)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Non-severe inpatient microbiology for CAP

A

Haemophilus influenzae
Streptococcus pneumoniae
Atypicals (Mycoplasma pneumoniae, chlamydophilia pneumoniae, Legionella pneuomophilia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Severe inpatient microbiology for CAP

A

Haemophilus influenzae
Streptococcus pneumoniae
Atypicals (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophilia)
Staph aureus
Gram negative bacilli (Klebsiella pneumonia, Burkholderia pseudomallei)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which microorganism implicated in CAP is endemic in Asia?

A

Burkholderia pseudomallei

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Severity of a CAP patient’s clinical presentation determines _____

A

Location of treatment (outpatient or inpatient)
Organisms that need to be covered
Empiric antibiotic selection
Route of antibiotic administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What scoring systems are used for risk stratification for CAP?

A

Pneumonia severity index
CURB-65 Score
IDSA/ATS Criteria for Severe CAP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IDSA/ATS Criteria for Severe CAP

A

> = 1 major criteria OR >=3 minor criteria
Major: mechanical ventilation, septic shock requiring vasoactive medications
Minor: RR>= 30 breaths per minute, PaO2 =<250, multilobar infiltrates, confusion/disorientation, uremia (urea >7mmol/L), leukopenia (WBC < 4x10^9/L), hypothermia (core temp < 36degC), hypotension requiring aggressive fluid resuscitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What antibiotic do you give to an outpatient with osteoporosis?

A

PO Amoxicillin first line, alternative is PO respiratory fluoroquinolone (levofloxacin or moxifloxacin) if penicillin allergy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which antibiotic do you give to an outpatient with asplenia?

A

PO Amoxicillin-clavulanate or cefuroxime PLUS PO macrolide (clarithromycin or azithromycin) or PO doxycycline

OR
PO Respiratory fluoroquinolone (levo and moxi) for those with penicillin allergy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

When do you need to cover for atypicals for an outpatient?

A

Comorbidities (heart, lung, kidney, liver diseases, DM, alcoholism, malignancy, asplenia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the empiric treatment for non-severe inpatient?

A

B-lactam (amoxicillin-clavulanate OR ceftriaxone) PLUS macrolide (clarithromycin or azithromycin) or doxycycline

OR respiratory FQ (levo, moxi) for severe penicillin allergy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Which beta-lactam has coverage for Burkholderia pseudomallei and is thus used for the standard regimen?

A

Ceftazidime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the empiric treatment for severe inpatient?

A

Beta-lactam (amoxicillin-clavulanate PLUS ceftazidime) AND macrolide (clarithromycin or azithromycin) or doxycycline

Penicillin allergy: respi FQ AND ceftazidime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the indications for anaerobic coverage?

A

Lung abscess

Empyema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the anaerobic microbes that are present?

A

Bacteriodes fragilis
Prevotella spp
Porphyromonas spp
Fusobacterium spp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the antibiotic to add if the current regimen has no anaerobic activity?

A

Clindamycin IV/PO, metronidazole IV/PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Which antibiotics from the standard regimen already has anaerobic activity?

A

Amoxicillin-clavulanate and moxifloxacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the indication for MRSA coverage for CAP?

A

Prior respiratory isolation of MRSA in last 1 year

Severe CAP only: hospitalisation and received IV antibiotics within last 90 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What antibiotics to add to standard regimen for those with additional MRSA coverage?

A

Vancomycin IV or linezolid IV/PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Why can’t daptomycin be used for MRSA coverage?

A

It is inactivated by lung surfactant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the indication for pseudomonal coverage?

A

Prior respiratory isolation of Pseudomonas aeruginosa in last 1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Do we need to add on additional antibiotics for pseudomonal coverage in a patient with severe CAP?

A

No, because ceftazidime already has pseudomonal coverage (for Burkholderia pseudomallei)

29
Q

What antibiotics can be added for additional pseudomonal coverage?

A

IV pip-tazo, ceftazidime IV, cefepime IV, meropenem IV, levofloxacin IV/PO

30
Q

What are the treatment consideration for CAP?

A

Respiratory FQs should not be used as first line for CAP

Adjunctive corticosteroid therapy

31
Q

Why are respiratory FQs not used as first line for CAP?

A

Delay diagnosis of TB
Reduce collateral damage (resistance with overuse)
Preserve activity for other gram=negative infections (cipro and levo are the only oral options for Pseudomonas)
Increased adverse effects (tendonitis, tendon rupture, neuropathy, hypoglycemia, CNS disturbances, QT prolongation)

32
Q

Why may corticosteroids be added as adjunctive therapy for CAP?

A

Reduce inflammation in the lungs

33
Q

What needs to be monitored for CAP treatment outcomes?

A

Safety (renal function, side effects like diarrhea, rash)
Efficacy
- Clinical improvements expected in 48-72 hours (decreased cough, chest pain, SOB, fever, WBC, tachypnea etc)
-Should not escalate antibiotic therapy in the 1st 72 hours
- Radiographic improvement lags behind, up to 4-6 weeks for resolution, only repeat during clinical deterioration

34
Q

When can you stop pseudomonal or MRSA coverage?

A

May be stopped in 48 hours if no MRSA or Pseudomonas aeruginosa is found on culture and patient is improving

35
Q

When can you step down the initial use of IV antibiotics for CAP?

A

If ALL the following criteria are met:

  • Hemodynamically stable
  • clinically improved/improving
  • afebrile >=24 hours
  • normally functioning GI tract
  • able to ingest PO medications
36
Q

What are the benefits of PO step-down therapy?

A

increased patient comfort and mobility
decrease risk of nosocomial-acquired bloodstream infections
decrease phlebitis
decrease preparation and administration time
decrease costs (drug, IV tubing, syringes, time)
facilitates discharge

37
Q

How to guide PO step down therapy?

A

If positive cultures, follow susceptibility test results
If no positive cultures, use same antibiotic or another antibiotic from the same class. May stop empiric coverage for MRSA, pseudomonas or Burkholderia in 48 hours if they are not found and are clinically improving.

38
Q

If burkholderia has not been isolated, which antibiotic can be removed during step down to PO therapy?

A

Ceftazidime

39
Q

What is the treatment duration for Burkholderia pseudomallei?

A

3-6 months

40
Q

What is the treatment duration for MRSA and pseudomonas?

A

7 days

41
Q

What is the minimum treatment duration for CAP?

A

5 days and patient must be clinically stable

42
Q

Prevention strategies for HAP/VAP?

A

Practice consistent hand hygiene
Judicious use of antibiotics and sedative medications
VAP specific (limit use of mechanical ventilation, minimise duration and deep levels of sedation, elevate head of bed by 30 degrees)

43
Q

Patient risk factors for HAP/VAP

A

Patient related (elderly, smoking, COPD, cancer, immunosuppression, prolonged hospitalisation, coma, impaired consciousness, malnutrition)

44
Q

Infection control risk factors for HAP/VAP

A

Hand hygiene compliance

Contaminated respiratory care devices

45
Q

Healthcare related factors for HAP/VAP

A 
Prior antibiotic use
Sedatives
Opioid analgesics
Mechanical ventilation 
Supine position
46
Q

What are the MDR strains for HAP/VAP?

A

Acinenobacter spp
Klebsiella pneumoniae
Pseudomonas aeruginosa

47
Q

What is the minimum requirement for empiric coverage for HAP/VAP?

A

MSSA and pseudomonas aeruginosa

48
Q

Additional coverage for HAP/VAP is dependent on what risk factors?

A

MRDO risk factors
Mortality risk factors
Hospital or unit’s bacteria susceptibility rates (antibiogram)

49
Q

What is acute renal replacement therapy an indication of?

A

Septic shock

50
Q

MDRO risk factors for HAP

A

Prior IV antibiotics use within 90 days

51
Q

MDRO risk factors for VAP

A 
Prior IV antibiotics use within 90 days 
Septic shock at time of VAP onset 
ARDS preceding VAP onset 
>= 5 days hospitalisation prior to VAP
Acute renal replacement therapy prior to VAP
52
Q

Mortality risk factors for HAP

A

Any one of:
Requiring mechanical ventilation as a result of HAP
In septic shock

53
Q

Do we need to cover for Burkholderia pseudomallei in HAP/VAP?

A

No need, as it is community acquired only (present in soil; patients in hospital will not be exposed to soil)

54
Q

What organisms do we need to cover for HAP?

A

Streptococcus pneumoniae
MSSA
Pseudomonas aeruginosa
antibiotic sensitive enterobacteriaceae (e coli, K pneumoniae, Enterobacter spp, Proteus spp, Serratia marcescens)

55
Q

Can ceftazidime be used for HAP?

A

No, because it lacks good gram + coverage; misses out Strep pneumo and MSSA

56
Q

What is the backbone regimen for HAP?

A

Pip/tazo, cefepime, imipenem, meropenem

OR

levofloxacin

57
Q

Who needs empiric MRSA coverage for HAP?

A

Mortality risk factors
MRDO risk factors
MRSA prevalence >20% or unknown

58
Q

If levofloxacin was used as the backbone regimen for HAP, what antibiotic can be given for additional gram negative coverage?

A

aminoglycosides (gentamicin, amikacin, tobramycin)

59
Q

When is ciprofloxacin used in the treatment of HAP?

A

As an add on treatment for additional gram negative coverage in patients who had a beta lactam as their backbone regimen

60
Q

What is the backbone regimen for VAP?

A

(same as HAP)
Pip/tazo, cefepime, imipenem, meropenem

OR

levofloxacin

61
Q

Who needs empiric MRSA coverage for VAP?

A

MRSA prevalence >10%

MRDO risk factors

62
Q

Who needs additional gram negative coverage for VAP?

A

MDRO risk factors

Single anti-pseudomonal agent with activity <90% or unknown

63
Q

If additional gram negative coverage for VAP is indicated, what antibiotics can be used?

A 
(Choose a different class from backbone regimen) 
Gentamicin, amikacin, tobramycin, ciprofloxacin, levofloxacin
64
Q

Why is additional gram negative coverage recommended empirically?

A

Empirically to broaden spectrum of gram negative coverage in patients who are at risk for MDRO or death (in case 1 agent does not provide adequate coverage)

65
Q

When to de-escalate for HAP/VAP?

A

Clinically improving; AND

Positive cultures with documented susceptibility; OR negative blood and respiratory cultures

66
Q

If a patient is treated with vancomycin, piptazo and gentamicin regimen initially and negative cultures came back, how do we de-escalate therapy?

A

We can stop vancomycin and gentamicin as we did not grow MRSA.
Stop gentamicin because nothing grew, so only keep coverage against MSSA and pseudomonas.

67
Q

When is clinical improvement expected in for HAP/VAP?

A

within 72 hours

68
Q

Treatment duration for HAP/VAP?

A

7 days regardless of pathogen

69
Q

Which antibiotics require renal dose adjustments for the treatment of HAP/VAP?

A

Pip-tazo, cefepime, meropenem, imipenem, ciprofloxacin, levofloxacin, gentamicin, amikacin, vancomycin
(everything except linezolid)

PR3124 FINALS (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions